Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine
The ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since its clinical management is characterized by very toxic therapeutics. In thi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/21/13368 |
| _version_ | 1797467903919915008 |
|---|---|
| author | Alessandro Parodi Ekaterina P. Kolesova Maya V. Voronina Anastasia S. Frolova Dmitry Kostyushev Daria B. Trushina Roman Akasov Tatiana Pallaeva Andrey A. Zamyatnin |
| author_facet | Alessandro Parodi Ekaterina P. Kolesova Maya V. Voronina Anastasia S. Frolova Dmitry Kostyushev Daria B. Trushina Roman Akasov Tatiana Pallaeva Andrey A. Zamyatnin |
| author_sort | Alessandro Parodi |
| collection | DOAJ |
| description | The ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since its clinical management is characterized by very toxic therapeutics. In this effort, nanomedicine showed the potential to improve the targeting of different drugs by improving their pharmacokinetics properties and to provide the means to generate new concept of treatments based on physical treatments and biologics. In this review, we considered different platforms that reached the clinical trial investigation, providing an objective analysis about their physical and chemical properties and the working mechanism at the basis of their tumoritr opic properties. With this review, we aim to help other scientists in the field in conceiving their delivering platforms for clinical translation by providing solid examples of technologies that eventually were tested and sometimes approved for human therapy. |
| first_indexed | 2024-03-09T18:59:23Z |
| format | Article |
| id | doaj.art-2c3e84784d2e46ceaf0c5eb07d1aa119 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T18:59:23Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-2c3e84784d2e46ceaf0c5eb07d1aa1192023-11-24T05:06:50ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-11-0123211336810.3390/ijms232113368Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of NanomedicineAlessandro Parodi0Ekaterina P. Kolesova1Maya V. Voronina2Anastasia S. Frolova3Dmitry Kostyushev4Daria B. Trushina5Roman Akasov6Tatiana Pallaeva7Andrey A. Zamyatnin8Scientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, RussiaScientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, RussiaScientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, RussiaScientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, RussiaScientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, RussiaInstitute of Molecular Theranostics, Sechenov First Moscow State Medical University, 119991 Moscow, RussiaInstitute of Molecular Theranostics, Sechenov First Moscow State Medical University, 119991 Moscow, RussiaScientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, RussiaScientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, RussiaThe ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since its clinical management is characterized by very toxic therapeutics. In this effort, nanomedicine showed the potential to improve the targeting of different drugs by improving their pharmacokinetics properties and to provide the means to generate new concept of treatments based on physical treatments and biologics. In this review, we considered different platforms that reached the clinical trial investigation, providing an objective analysis about their physical and chemical properties and the working mechanism at the basis of their tumoritr opic properties. With this review, we aim to help other scientists in the field in conceiving their delivering platforms for clinical translation by providing solid examples of technologies that eventually were tested and sometimes approved for human therapy.https://www.mdpi.com/1422-0067/23/21/13368nanomedicinetargeted therapiesEPRSPIONAbraxaneDoxil |
| spellingShingle | Alessandro Parodi Ekaterina P. Kolesova Maya V. Voronina Anastasia S. Frolova Dmitry Kostyushev Daria B. Trushina Roman Akasov Tatiana Pallaeva Andrey A. Zamyatnin Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine International Journal of Molecular Sciences nanomedicine targeted therapies EPR SPION Abraxane Doxil |
| title | Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine |
| title_full | Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine |
| title_fullStr | Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine |
| title_full_unstemmed | Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine |
| title_short | Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine |
| title_sort | anticancer nanotherapeutics in clinical trials the work behind clinical translation of nanomedicine |
| topic | nanomedicine targeted therapies EPR SPION Abraxane Doxil |
| url | https://www.mdpi.com/1422-0067/23/21/13368 |
| work_keys_str_mv | AT alessandroparodi anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT ekaterinapkolesova anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT mayavvoronina anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT anastasiasfrolova anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT dmitrykostyushev anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT dariabtrushina anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT romanakasov anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT tatianapallaeva anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine AT andreyazamyatnin anticancernanotherapeuticsinclinicaltrialstheworkbehindclinicaltranslationofnanomedicine |